Articles: low-back-pain.
-
Adult scoliosis is sometimes associated with back pain and severe curves can progress over time. Despite scoliosis has been estimated to affect up to 68% of the population over 60, there is scant literature about conservative treatment for adult scoliosis. Recently, we tested a new brace designed to alleviate pain for adult patients with chronic pain secondary to scoliosis. The study aims to test the efficacy of a prefabricated brace in reducing pain in adult scoliosis patients. ⋯ The prefabricated brace showed a significant improvement at 6 months of worst, leg and back pain in most patients in a group of adult women with IS and cLBP. The quality of life didn't change in a clinically significant way even if the patients reported satisfaction with the treatment. Trial registration number and date of registration: ClinicalTrials.gov Identifier: NCT02643290, December 31, 2015.
-
The COVID-19 pandemic and the containment measures such as social distancing, mobility restrictions and quarantine have significantly impacted the delivery of healthcare services, with possible negative effects on low back pain patients. In this study, we used an innovative agent-based model to quantify the effects of COVID-19 on the prevalence and severity of low back pain in the general population. ⋯ "Optimal lockdown parameters" which minimize the impact on low back pain while preserving the effects on infection spread and mortality could not be identified. Policies favouring a prompt resumption of treatments after the lockdown may be effective in shortening the duration of its negative effects.
-
Yes, it is somewhat effective. Exercise therapy-including general exercise, yoga, Pilates, and motor control exercise-has been shown to modestly decrease pain in chronic low back pain (LBP); levels of benefit in short- (≤ 3 months) and long- (≥ 1 year) term follow-up range from 4% to 15% improvement (strength of recommendation [SOR] A, based on a systematic review of randomized controlled trials [RCTs]). Exercise therapy may improve function and decrease work disability in subacute and chronic LBP, respectively (SOR A, based on a meta-analysis of RCTs). Exercise therapy has not been associated with improvement in acute LBP (SOR A, based on a meta-analysis of RCTs).
-
Randomized Controlled Trial
The mediating effect of pain catastrophizing on pain intensity: the influence of the timing of assessments.
Pain catastrophizing underpins several psychosocial theories of pain, but there is limited evidence to support the proposal that changes in pain catastrophizing cause changes in pain. Results from mediation analyses have conflicting results, and one reason for these might be the timing of the assessment of pain catastrophizing. This study aimed to test the effect of the timing of the assessment of pain catastrophizing on its mediating role on pain intensity. ⋯ The timing of the assessment influenced the mediating role of pain catastrophizing on pain intensity. These results raise questions on the casual role that pain catastrophizing has on pain intensity. Psychosocial interventions such as clinical hypnosis can reduce pain intensity even when there has been no change in pain catastrophizing.
-
Randomized Controlled Trial
An implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial.
Chronic low back pain can be caused by impaired control and degeneration of the multifidus muscles and consequent functional instability of the lumbar spine. Available treatment options have limited effectiveness and prognosis is unfavorable. We conducted an international randomized, double-blind, sham-controlled trial at 26 multidisciplinary centers to determine safety and efficacy of an implantable, restorative neurostimulator designed to restore multifidus neuromuscular control and facilitate relief of symptoms (clinicaltrials.gov identifier: NCT02577354). ⋯ Prespecified secondary outcomes and analyses were consistent with a modest but clinically meaningful treatment benefit at 120 days. Improvements from baseline, which continued to accrue in all outcome measures after conclusion of the double-blind phase, were clinically important at 1 year. The incidence of serious procedure- or device-related adverse events (3.9%) compared favorably with other neuromodulation therapies for chronic pain.